MS Pharma gibt strategische Wachstumsinvestition der Olayan Financing Company bekannt
MS Pharma has announced that the Olayan Financing Company (OFC) has acquired a minority stake in the company. This partnership aims to enhance the strategic growth phase of MS Pharma and demonstrates the company’s commitment to innovation, regional expansion, and long-term value creation. It also marks the beginning of a long-term collaboration between OFC and the existing majority shareholders of MS Pharma, who have a history of strong leadership and performance in the pharmaceutical sector.
The transaction involves MS Pharma issuing new equity in exchange for a significant cash investment from OFC, thereby granting OFC a minority stake in the company. This investment is expected to strengthen MS Pharma's financial position and flexibility, supporting its ambitious growth plans in the MENA region, including the development of its biosimilar portfolio and supply chain resilience.
Ghiath Sukhtian, Chairman of MS Pharma, expressed enthusiasm about the partnership, stating, “We are very excited and honored to welcome OFC as a partner in the company. Their global operational and investment expertise, along with their deep roots in Saudi Arabia, will create significant value for MS Pharma and benefit all our stakeholders.”
Kalle Kaend, CEO of MS Pharma, added that the investment comes at an exciting turning point for the company, allowing it to deepen its expertise in biologics and expand its reach in Saudi Arabia and the MENA region. He emphasized the intent to leverage OFC’s established network to achieve ambitious goals while building a strong organization that delivers long-term value.
Nabeel Al-Amudi, CEO of OFC, noted that MS Pharma has established itself as a leading pharmaceutical platform in the region with strong competencies in generics and biologics, and he looks forward to collaborating during this growth phase to support its expansion in accordance with their long-term investment philosophy.
MS Pharma is recognized for its leadership in biosimilars, particularly in Saudi Arabia, where its biologics manufacturing facility was the first in the kingdom to receive SFDA-GMP certification. This year, the company aims to become the first provider of locally manufactured biologics in the Saudi market, underscoring its commitment to localization in line with Saudi Arabia's National Biotechnology Strategy and Vision 2030.